Clinical Trial Update: Open-Label Extension Study to Pioneer Study 6058-SCD-101 [Phase 2]

View source ↗

Summary

Open-label extension of the Phase 2 Pioneer study 6058-SCD-101 for sickle cell disease. Enrollment is by invitation and ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• FTX-6058

Snippet

Sponsor: Fulcrum Therapeutics | Conditions: Sickle Cell Disease | Phase 2 | Status: ENROLLING_BY_INVITATION